Key Points
- EVP James Barry sold 700 shares on Nov. 6 at an average of $306.18 for total proceeds of $214,326, reducing his holding by 57.85% to 510 shares (≈$156,151.80), according to an SEC filing.
- Bio‑Rad reported Q3 EPS of $2.26 versus the $2.30 consensus and revenue of $653M (up 0.5% y/y); despite a negative net margin (26.43%), analysts maintain a consensus "Moderate Buy" with a $358.50 target.
Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) EVP James Barry sold 700 shares of the firm's stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total transaction of $214,326.00. Following the transaction, the executive vice president directly owned 510 shares of the company's stock, valued at approximately $156,151.80. This trade represents a 57.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Bio-Rad Laboratories Price Performance
Shares of BIO opened at $307.65 on Tuesday. The business's 50-day moving average is $300.20 and its two-hundred day moving average is $268.14. The company has a market capitalization of $8.33 billion, a P/E ratio of -12.66 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $373.69. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The company had revenue of $653.00 million during the quarter, compared to analyst estimates of $651.30 million. During the same period last year, the firm earned $2.01 EPS. The business's quarterly revenue was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.
Hedge Funds Weigh In On Bio-Rad Laboratories
Large investors have recently added to or reduced their stakes in the stock. Quent Capital LLC purchased a new position in Bio-Rad Laboratories during the third quarter valued at $25,000. Caitong International Asset Management Co. Ltd lifted its stake in Bio-Rad Laboratories by 3,633.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company's stock valued at $27,000 after buying an additional 109 shares in the last quarter. Quarry LP acquired a new stake in Bio-Rad Laboratories in the 1st quarter worth about $29,000. Farther Finance Advisors LLC increased its stake in Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company's stock worth $29,000 after buying an additional 36 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. Zacks Research raised shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 26th. Royal Bank Of Canada increased their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a "buy" rating in a research report on Thursday, October 30th. Wall Street Zen raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, November 1st. Finally, Weiss Ratings raised shares of Bio-Rad Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, October 30th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $358.50.
View Our Latest Report on Bio-Rad Laboratories
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
